


# UPDATE ON TEDUGLUTIDE (REVESTIVE®)



The HSE introduced a managed access protocol (MAP) for teduglutide (Revestive®) in January 2021. The aim of the MAP is to provide patients with Short Bowel Syndrome and Type III intestinal failure whose condition is stable and currently on long-term parenteral nutrition, with access to teduglutide under the High Tech Arrangement.

To date, the HSE have approved two prescribers for teduglutide in specialist centres under this protocol. By November 2023, the majority of patients accessing treatment with teduglutide each month under the High Tech Arrangement are male (70%) with a mean age of 30 years.

**January 2024**

**HSE Medicines Management Programme.**